D283 Med, a Cell Line Derived from Peritoneal Metastatic Medulloblastoma: A Good Choice for Missing Protein Discovery

Yuanliang Zhang1,2, Keren Zhang1,2, Fanyu Bu3

  • 1BGI-Shenzhen, Beishan Industrial Zone 11th Building, Yantian District, Shenzhen, Guangdong 518083, China.

Insights

Researchers identified 12 missing proteins (MPs) in a metastatic brain cancer cell line, highlighting the importance of selecting appropriate cell lines for discovering these elusive proteins.

Area of Science:

  • Proteomics
  • Cancer Biology
  • Human Protein Research

Background:

  • The Chromosome-Centric Human Proteome Project (C-HPP) aims to discover all human proteins.
  • Protein discovery has reached a bottleneck, with protein expression being tissue-specific.
  • Brain tissue and cells are underrepresented in missing protein (MP) discovery efforts.

Purpose of the Study:

  • To identify missing proteins (MPs) in human brain cancer cell lines.
  • To evaluate the impact of material selection on MP discovery.
  • To validate identified MPs using synthesized peptides.

Main Methods:

  • Utilized a shotgun proteomics workflow with peptide fractionation.
  • Analyzed a metastatic brain cancer cell line (D283 Med) and a nonmetastatic cell line (U-118 MG).
  • Employed parallel reaction monitoring (PRM) for MP validation against synthesized peptides.

Main Results:

  • Identified 12 MPs in the D283 Med cell line with high confidence (<1% FDR).
  • Found only one MP in the U-118 MG cell line using the same protocol.
  • Successfully validated the 12 identified MPs through comparison with synthesized peptides.

Conclusions:

  • The choice of experimental material (cell line or tissue) is critical for successful MP discovery.
  • Metastatic brain cancer cell lines are a promising source for identifying brain-specific MPs.
  • This study advances the discovery of missing proteins in the human proteome.

Related Concept Videos